AR and prostate cancer: This variant of AR lacks the ligand‐binding domain (a target of anti‐AR drugs such as enzalutamide and abiraterone), but retains its constitutive activity.33 Consequently, ARv7 causes resistance to anti‐AR drugs as confirmed in patients with prostate cancer.33 Given the common AR expression and the lack of ARv7 in the majority of AR + EMPD, these patients may be amenable for the trials with anti‐AR drugs.31, 34